Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 3 2Phase NA 1Phase 2/3 1Phase 2 1Phase 1 1

Status

Completed 4Unknown 2Terminated 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Classical hematology 1

Conditions

Neoplasms 2Venous Thrombosis 1Venous Thromboembolism 1

Interventions

Cisplatin 130Radiotherapy 94Carboplatin 85Paclitaxel 78Fluorouracil 78Cyclophosphamide 77Gemcitabine 72Capecitabine 66Docetaxel 65Doxorubicin 60Oxaliplatin 59Etoposide 57Leucovorin 49Vincristine 47Chemotherapy, Adjuvant 42Cytarabine 38Dexamethasone 35Drug Therapy 33Bevacizumab 30Epirubicin 29Neoadjuvant Therapy 28Pemetrexed 27Tamoxifen 25Prednisone 24Irinotecan 24Rituximab 21Methotrexate 21Radiotherapy, Intensity-Modulated 19apatinib 18Vinorelbine 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Unknown × Rivaroxaban × Clear all
NCT04999176 2021-08-10

VALERIA

Science Valley Research Institute

Phase 3 Unknown
440 enrolled
Classical hematology

Neoplasms, Venous Thromboembolism

NCT04309240 2020-03-16

Rivaroxaban for Thromboprophylaxis in High-risk Cancer Patients With Totally Implantable Access Ports

LiuZhou People's Hospital

Phase 3 Unknown
204 enrolled

Neoplasms, Venous Thrombosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡